Home/Pipeline/Oncology Generics

Oncology Generics

Various cancers

CommercialActive

Key Facts

Indication

Various cancers

Phase

Commercial

Status

Active

Company

Aurobindo Pharma

About Aurobindo Pharma

Aurobindo Pharma Limited is a vertically integrated pharmaceutical company founded in 1986, headquartered in Hyderabad, India. The company has established itself as a major player in the global generics market with a diverse portfolio spanning antibiotics, ARVs, CVS, CNS, gastroenterology, and other therapeutic segments. With multiple manufacturing facilities across India, the US, and other countries, Aurobindo has built a robust supply chain and regulatory compliance framework serving both developed and emerging markets.

View full company profile

Therapeutic Areas

Anti-infectives Cardiovascular CNS Gastroenterology Oncology HIV/AIDS Respiratory Biosimilars

Other Various cancers Drugs

Drug	Company	Phase	Status
Retifanlimab	Eli Lilly	Phase 2/3	Active
Imfinzi (durvalumab)	AstraZeneca	Approved	Commercial
Lynparza (olaparib)	Merck	Commercial	Active
Oncology Portfolio	Pfizer	Phase 1-3	Multiple Active Programs
PD-1 Inhibitor	Akeso	Phase 2/3	Active
Mitoxantrone Liposome	CSPC Pharmaceutical Group Limited	Phase 3	Active
Biosimilar Bevacizumab	Cipla	Commercial	Active
Tazverik (tazemetostat)	Eisai	Commercial	Discontinuation announced
Opdivo (nivolumab)	Ono Pharmaceutical	Approved	Commercial
Oncology APIs (e.g., Sorafenib, Lenalidomide)	Laurus Labs	Commercial/Filed	Active
Tumor Marker Portfolio (PSA, CA125, etc.)	H.U. Group Holdings	Commercial	Active
Logic-gated Switch-DARPins	Molecular Partners	Preclinical	Platform